While risk stratification traditionally relies on clinical parameters such as Gleason score, tumor staging, and serum PSA levels, these measures alone fail to capture the molecular heterogeneity of the disease, leading to uncertainty in patient prognosis and treatment decisions68. This evidence concerns the gene KLK3 and neoplasm.